Spots Global Cancer Trial Database for An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
Official Title: An Open-Label Expanded Access Protocol for Apalutamide Treatment of Subjects With Non Metastatic Castration-Resistant Prostate Cancer
Study ID: NCT03523338
Conditions
Study Description
Brief Summary: The purpose of this study is to collect additional safety data until apalutamide is commercially available for participants with non-metastatic castrate-resistant prostate cancer (NM-CRPC).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Ynova Pesquisa Clinica, Florianopolis, , Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, , Brazil
Ensino e Terapia de Inovacao Clinica AMO - Etica, Salvador, , Brazil
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, , Brazil
Fundacao Antonio Prudente - A.C. Camargo Cancer Center, Sao Paulo, , Brazil
Núcleo de Pesquisa São Camilo, São Paulo, , Brazil
Hospital Pablo Tobon Uribe, Medellin, , Colombia
Instituto Nacional de Cancerologia, Mexico, , Mexico
i Can Oncology Center, Monterrey, , Mexico
Oncologia Integral Satelite, Naucalpan, , Mexico
Centro Oncologico Estatal ISSEMYM, Toluca, , Mexico
Farmaco Oncología especializada S.A. de C.V, Zapopan, , Mexico
Contact Details
Name: Aragon Pharmaceuticals, Inc. Clinical Trial
Affiliation: Aragon Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
